BRIEF-Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Reuters2026/09/23 11:05Oruka Therapeutics Inc ORKA.O:
ORUKA THERAPEUTICS ANNOUNCES POSITIVE WEEK 28 DATA FOR ORKA-001 FROM THE ONGOING EVERLAST-A TRIAL SHOWING DEEPENING OF RESPONSES WITHOUT ADDITIONAL DOSING
ORUKA THERAPEUTICS - ORKA-001 MAINTAINS FAVORABLE SAFETY AND TOLERABILITY PROFILE THROUGH WEEK 28
ORUKA THERAPEUTICS - TWO SERIOUS ADVERSE EVENTS REPORTED, NEITHER DEEMED DRUG RELATED
ORUKA THERAPEUTICS - 16-WEEK EVERLAST-B DATA EXPECTED IN FOURTH QUARTER 2026
ORUKA THERAPEUTICS - 52-WEEK EVERLAST-A DATA EXPECTED IN DECEMBER 2026
Source text: ID:nGNX10yvmc
Further company coverage: ORKA.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nidec shares plunge 17%
BoJ Minutes: Members agree financial conditions remain accommodative
Iran’s seven-day reopening plan for the Hormuz Strait was rejected by Trump; Brent crude oil rises above $106
Iran insists on a seven-day proposal to reopen the Strait of Hormuz, but this plan has been rejected by U.S. President Trump, which may further delay the reopening of this crucial waterway.
New York Silver Futures Drop 1% to $64.15 per Ounce
Crypto prices
More
